总览

使用EasySep™人CD4+ T细胞分选试剂盒，可轻松高效地从新鲜或冻存的人外周血单个核细胞（PBMCs）或白细胞单采样本中通过免疫磁珠负选获得高纯度人CD4+ T细胞。EasySep™技术结合单克隆抗体的特异性和免磁柱系统的简便性，已在发表的研究中广泛应用超过20年。

在该 EasySep™负选流程中，非目的细胞会被抗体复合物与磁珠标记。表达以下标记物的非目的细胞将被靶向去除：CD8、CD14、CD16、CD19、CD36、CD56、CD66b、CD123、TCRgd 和GlyA。通过EasySep™磁极将被磁珠标记的细胞与未被标记的目的细胞分离，将目的细胞简单倾倒或移液吸取至新试管中。仅需8分钟即可完成磁珠分选，获得的 CD4+ T细胞可用于流式细胞术、细胞培养或DNA/RNA提取等下游应用。

该试剂盒可替代EasySep™人CD4+ T细胞富集试剂盒 (产品号 #19052) 以实现更快速地细胞分选。

如需从白细胞单采样本中大规模分选人CD4+ T细胞，请选用大包装（1×10^10细胞）试剂盒（产品号 #100-0696）。

了解更多关于免疫磁珠EasySep™技术的工作原理，或如何通过RoboSep™实现免疫磁珠细胞分选全自动化。或直接选用 EasySep™人CD4+ 分选试剂盒提供的即用型、符合伦理道德的冻存人外周血CD4+ T原代细胞。探索其他针对您的工作流程优化的产品，包括培养基、补充剂、抗体等。

在该 EasySep™负选流程中，非目的细胞会被抗体复合物与磁珠标记。表达以下标记物的非目的细胞将被靶向去除：CD8、CD14、CD16、CD19、CD36、CD56、CD66b、CD123、TCRgd 和GlyA。通过EasySep™磁极将被磁珠标记的细胞与未被标记的目的细胞分离，将目的细胞简单倾倒或移液吸取至新试管中。仅需8分钟即可完成磁珠分选，获得的 CD4+ T细胞可用于流式细胞术、细胞培养或DNA/RNA提取等下游应用。

该试剂盒可替代EasySep™人CD4+ T细胞富集试剂盒 (产品号 #19052) 以实现更快速地细胞分选。

如需从白细胞单采样本中大规模分选人CD4+ T细胞，请选用大包装（1×10^10细胞）试剂盒（产品号 #100-0696）。

了解更多关于免疫磁珠EasySep™技术的工作原理，或如何通过RoboSep™实现免疫磁珠细胞分选全自动化。或直接选用 EasySep™人CD4+ 分选试剂盒提供的即用型、符合伦理道德的冻存人外周血CD4+ T原代细胞。探索其他针对您的工作流程优化的产品，包括培养基、补充剂、抗体等。

在该 EasySep™负选流程中，非目的细胞会被抗体复合物与磁珠标记。表达以下标记物的非目的细胞将被靶向去除：CD8、CD14、CD16、CD19、CD36、CD56、CD66b、CD123、TCRgd 和GlyA。通过EasySep™磁极将被磁珠标记的细胞与未被标记的目的细胞分离，将目的细胞简单倾倒或移液吸取至新试管中。仅需8分钟即可完成磁珠分选，获得的 CD4+ T细胞可用于流式细胞术、细胞培养或DNA/RNA提取等下游应用。

该试剂盒可替代EasySep™人CD4+ T细胞富集试剂盒 (产品号 #19052) 以实现更快速地细胞分选。

如需从白细胞单采样本中大规模分选人CD4+ T细胞，请选用大包装（1×10^10细胞）试剂盒（产品号 #100-0696）。

了解更多关于免疫磁珠EasySep™技术的工作原理，或如何通过RoboSep™实现免疫磁珠细胞分选全自动化。或直接选用 EasySep™人CD4+ 分选试剂盒提供的即用型、符合伦理道德的冻存人外周血CD4+ T原代细胞。探索其他针对您的工作流程优化的产品，包括培养基、补充剂、抗体等。

在该 EasySep™负选流程中，非目的细胞会被抗体复合物与磁珠标记。表达以下标记物的非目的细胞将被靶向去除：CD8、CD14、CD16、CD19、CD36、CD56、CD66b、CD123、TCRgd 和GlyA。通过EasySep™磁极将被磁珠标记的细胞与未被标记的目的细胞分离，将目的细胞简单倾倒或移液吸取至新试管中。仅需8分钟即可完成磁珠分选，获得的 CD4+ T细胞可用于流式细胞术、细胞培养或DNA/RNA提取等下游应用。

该试剂盒可替代EasySep™人CD4+ T细胞富集试剂盒 (产品号 #19052) 以实现更快速地细胞分选。

如需从白细胞单采样本中大规模分选人CD4+ T细胞，请选用大包装（1×10^10细胞）试剂盒（产品号 #100-0696）。

了解更多关于免疫磁珠EasySep™技术的工作原理，或如何通过RoboSep™实现免疫磁珠细胞分选全自动化。或直接选用 EasySep™人CD4+ 分选试剂盒提供的即用型、符合伦理道德的冻存人外周血CD4+ T原代细胞。探索其他针对您的工作流程优化的产品，包括培养基、补充剂、抗体等。

磁体兼容性
• EasySep™ Magnet (Catalog #18000) • “The Big Easy” EasySep™ Magnet (Catalog #18001) • Easy 50 EasySep™ Magnet (Catalog #18002) • EasyPlate™ EasySep™ Magnet (Catalog 18102) • EasyEights™ EasySep™ Magnet (Catalog #18103) • RoboSep™-S (Catalog #21000) • Easy 250 EasySep™ Magnet (Catalog #100-0821)

亚型
细胞分选试剂盒

细胞类型
T 细胞，T 细胞，CD4+

种属
人

样本来源
Leukapheresis，PBMC

筛选方法
Negative

应用
细胞分选

品牌
EasySep，RoboSep

研究领域
免疫

查看更多显示更少

实验数据

CD4+ T cell separation using EasySep™ Human CD4+ T Cell Isolation Kit

Figure 1. EasySep™ Human CD4+ T Cell Isolation Kit

Starting with human peripheral blood mononuclear cells (PBMCs), the CD4+ T cell (CD3+CD4+) content of the isolated fraction is typically 94.8 ± 2.3% (mean ± SD).

产品说明书及文档

请在《产品说明书》中查找相关支持信息和使用说明，或浏览下方更多实验方案。

Document Type

Product Name

Catalog #

Lot #

Language

Document Type

Product Information Sheet

Product Name

EasySep™ Human CD4+ T Cell Isolation Kit

Catalog #

100-0696

Lot #

All

Language

English

Document Type

Product Information Sheet 1

Product Name

EasySep™ Human CD4+ T Cell Isolation Kit

Catalog #

17952

Lot #

All

Language

English

Document Type

Product Information Sheet 2

Product Name

EasySep™ Human CD4+ T Cell Isolation Kit

Catalog #

17952

Lot #

All

Language

Multi

Document Type

Product Information Sheet 1

Product Name

RoboSep™ Human CD4+ T Cell Isolation Kit

Catalog #

17952RF

Lot #

All

Language

Multi

Document Type

Product Information Sheet 2

Product Name

RoboSep™ Human CD4+ T Cell Isolation Kit

Catalog #

17952RF

Lot #

All

Language

English

Document Type

Safety Data Sheet 1

Product Name

EasySep™ Human CD4+ T Cell Isolation Kit

Catalog #

17952

Lot #

All

Language

English

Document Type

Safety Data Sheet 2

Product Name

EasySep™ Human CD4+ T Cell Isolation Kit

Catalog #

17952

Lot #

All

Language

English

Document Type

Safety Data Sheet 1

Product Name

RoboSep™ Human CD4+ T Cell Isolation Kit

Catalog #

17952RF

Lot #

All

Language

English

Document Type

Safety Data Sheet 2

Product Name

RoboSep™ Human CD4+ T Cell Isolation Kit

Catalog #

17952RF

Lot #

All

Language

English

Document Type

Safety Data Sheet 3

Product Name

RoboSep™ Human CD4+ T Cell Isolation Kit

Catalog #

17952RF

Lot #

All

Language

English

应用领域

本产品专为以下研究领域设计，适用于工作流程中的高亮阶段。探索这些工作流程，了解更多我们为各研究领域提供的其他配套产品。

Research Area

Workflow Stages

Workflow Stages for T Cell Research

Cell Sourcing

Cell Isolation

Cell Activation, Expansion, and Differentiation

Cell Characterization

Workflow Stages for T Cell Engineering

Cell Isolation

Cell Activation, Expansion, and Differentiation

Cell Characterization

Cell Cryopreservation

Workflow Stages for T Cell Therapy Development

View All

Can EasySep™ be used for either positive or negative selection?

Yes. The EasySep™ kits use either a negative selection approach by targeting and removing unwanted cells or a positive selection approach targeting desired cells. Depletion kits are also available for the removal of cells with a specific undesired marker (e.g. GlyA).

How does the separation work?

Magnetic particles are crosslinked to cells using Tetrameric Antibody Complexes (TAC). When placed in the EasySep™ Magnet, labeled cells migrate to the wall of the tube. The unlabeled cells are then poured off into a separate fraction.

Which columns do I use?

The EasySep™ procedure is column-free. That's right - no columns!

How can I analyze the purity of my enriched sample?

The Product Information Sheet provided with each EasySep™ kit contains detailed staining information.

Can EasySep™ separations be automated?

Yes. RoboSep™, the fully automated cell separator, automates all EasySep™ labeling and cell separation steps.

Can EasySep™ be used to isolate rare cells?

Yes. We recommend a cell concentration of 2x10⁸ cells/mL and a minimum working volume of 100 µL. Samples containing 2x10⁷ cells or fewer should be suspended in 100 µL of buffer.

Are the EasySep™ magnetic particles FACS-compatible?

Yes, the EasySep™ particles are flow cytometry-compatible, as they are very uniform in size and about 5000X smaller than other commercially available magnetic beads used with column-free systems.

Can the EasySep™ magnetic particles be removed after enrichment?

No, but due to the small size of these particles, they will not interfere with downstream applications.

Can I alter the separation time in the magnet?

Yes; however, this may impact the kit's performance. The provided EasySep™ protocols have already been optimized to balance purity, recovery and time spent on the isolation.

For positive selection, can I perform more than 3 separations to increase purity?

Yes, the purity of targeted cells will increase with additional rounds of separations; however, cell recovery will decrease.

How does the binding of the EasySep™ magnetic particle affect the cells? is the function of positively selected cells altered by the bound particles?

Hundreds of publications have used cells selected with EasySep™ positive selection kits for functional studies. Our in-house experiments also confirm that selected cells are not functionally altered by the EasySep™ magnetic particles.

If particle binding is a key concern, we offer two options for negative selection. The EasySep™ negative selection kits can isolate untouched cells with comparable purities, while RosetteSep™ can isolate untouched cells directly from whole blood without using particles or magnets.

Identification of Mechanisms by Which Genetic Susceptibility Loci Influence Systemic Sclerosis Risk Using Functional Genomics in Primary T Cells and Monocytes. D. Gonz\'alez-Serna et al. Arthritis & rheumatology (Hoboken, N.J.) 2023 jun

Abstract

OBJECTIVE Systemic sclerosis (SSc) is a complex autoimmune disease with a strong genetic component. However, most of the genes associated with the disease are still unknown because associated variants affect mostly noncoding intergenic elements of the genome. We used functional genomics to translate the genetic findings into a better understanding of the disease. METHODS Promoter capture Hi-C and RNA-sequencing experiments were performed in CD4+ T cells and CD14+ monocytes from 10 SSc patients and 5 healthy controls to link SSc-associated variants with their target genes, followed by differential expression and differential interaction analyses between cell types. RESULTS We linked SSc-associated loci to 39 new potential target genes and confirmed 7 previously known SSc-associated genes. We highlight novel causal genes, such as CXCR5, as the most probable candidate gene for the DDX6 locus. Some previously known SSc-associated genes, such as IRF8, STAT4, and CD247, showed cell type-specific interactions. We also identified 15 potential drug targets already in use in other similar immune-mediated diseases that could be repurposed for SSc treatment. Furthermore, we observed that interactions were directly correlated with the expression of important genes implicated in cell type-specific pathways and found evidence that chromatin conformation is associated with genotype. CONCLUSION Our study revealed potential causal genes for SSc-associated loci, some of them acting in a cell type-specific manner, suggesting novel biologic mechanisms that might mediate SSc pathogenesis.

View publication

Discovery of potent immune-modulating molecule taccaoside A against cancers from structures-active relationships of natural steroidal saponins. Z. Dai et al. Phytomedicine : international journal of phytotherapy and phytopharmacology 2022 sep

Abstract

BACKGROUND In recent years, the T-cell therapy and immune checkpoint inhibitors toward CTLA-4 and PD-1/PD-L1 axis antibody therapy have acquired encouraging success. However, most of patients were still not benefited with lots of troubles, such as low penetration of tissues/cells, strong immunogenicity and cytokine release syndrome, and long manufacturing process and expensive costs. By contrast, the immune-modulating small molecules possessed natural advantages to overcome these obstacles and might achieve greater success. PURPOSE Exploring the potent immune-modulating natural small molecules and revealing what kinds of molecules or structures with the immunomodulatory activity against cancers. METHODS A novel non-cytotoxic T-cell immunomodulating screening model was used to identify the cytotoxic/selective/immunomodulatory bioactivity for 148 natural steroidal saponins. The structure-activity relationships (SARs) research was used to reveal the key groups for immunomodulation/cytotoxicity/selectivity. The negative selection was used to isolate and purify the T-cell. The cell viability assay was used to measure the anti-cancer effect in vitro. The ELISA assay was used to detect the cytokines for IL-1$\beta$, IL-6, TNF-$\alpha$, IFN-$\gamma$, IL-12, perforin and granzyme B (GZMB). The western blotting assay was used to research the immunomodulatory mechanism. The siRNA knockdown was used to generate the IFN-$\gamma$ resistant melanoma cells. The NOG immune-deficient mice were used to evaluate the anti-tumor efficacy in vivo. The peripheral blood samples from 10 cancer patients were used to detect the broad population anti-tumor efficacy. RESULTS It was reported that the correlation among structures and immunomodulation/ cytotoxicity/selectivity, in which opening ring-F with 26-O-glucopyranosyl, disaccharide and trisaccharide chains at C-3, steric hindrance and polarity of C-22 were key immunomodulatory groups. Moreover, taccaoside A was identified as the most potent candidate against cancer cells, including non-small cell lung cancer, triple negative breast cancer, and the IFN-$\gamma$ resistant melanoma, partly through enhancing T lymphocyte mTORC1-Blimp-1 signal to secrete GZMB. Besides, 10 patients derived T-cell also would be modulated against cancer cells in vitro. Moreover, the overall survival was great extended (>140 days vs 93 days) with nearly 100% tumor burden disappearance (0 mm3vs 1006 ± 79.5 mm3) in mice. CONCLUSION This work demonstrated one possibility for this concerned purpose, and identified a potent immune-modulating natural molecule taccaoside A, which might contribute to cancer immunotherapy in future.

View publication

ABCA1, TCF7, NFATC1, PRKCZ, and PDGFA DNA methylation as potential epigenetic-sensitive targets in acute coronary syndrome via network analysis. T. Infante et al. Epigenetics 2022 may

Abstract

Acute coronary syndrome (ACS) is the most severe clinical manifestation of coronary heart disease.We performed an epigenome-wide analysis of circulating CD4+ and CD8+ T cells isolated from ACS patients and healthy subjects (HS), enrolled in the DIANA clinical trial, by reduced-representation bisulphite sequencing (RRBS). In CD4+ T cells, we identified 61 differentially methylated regions (DMRs) associated with 57 annotated genes (53% hyper- and 47% hypo-methylated) by comparing ACS patients vs HS. In CD8+ T cells, we identified 613 DMRs associated with 569 annotated genes (28% hyper- and 72% hypo-methylated) in ACS patients as compared to HS. In CD4+vs CD8+ T cells of ACS patients we identified 175 statistically significant DMRs associated with 157 annotated genes (41% hyper- and 59% hypo-methylated). From pathway analyses, we selected six differentially methylated hub genes (NFATC1, TCF7, PDGFA, PRKCB, PRKCZ, ABCA1) and assessed their expression levels by q-RT-PCR. We found an up-regulation of selected genes in ACS patients vs HS (P < 0.001). ABCA1, TCF7, PDGFA, and PRKCZ gene expression was positively associated with CK-MB serum concentrations (r = 0.75, P = 0.03; r = 0.760, P = 0.029; r = 0.72, P = 0.044; r = 0.74, P = 0.035, respectively).This pilot study is the first single-base resolution map of DNA methylome by RRBS in CD4+ and CD8+ T cells and provides specific methylation signatures to clarify the role of aberrant methylation in ACS pathogenesis, thus supporting future research for novel epigenetic-sensitive biomarkers in the prevention and early diagnosis of this pathology.

View publication

View All Publications

EasySep™人CD4+ T细胞分选试剂盒

产品号 #（选择产品）

产品号 #17952_C

产品优势

产品组分包括

总览

实验数据

产品说明书及文档

应用领域

相关材料与文献

Request Pricing

更多信息

Scientists Helping Scientists™

种属	Human
Magnet Compatibility	• EasySep™ Magnet (Catalog #18000) • “The Big Easy” EasySep™ Magnet (Catalog #18001) • Easy 50 EasySep™ Magnet (Catalog #18002) • EasyPlate™ EasySep™ Magnet (Catalog 18102) • EasyEights™ EasySep™ Magnet (Catalog #18103) • RoboSep™-S (Catalog #21000) • Eas
样本来源	Leukapheresis, PBMC
Selection Method	Negative

EasySep™人CD4+ T细胞分选试剂盒

产品号 #（选择产品）

产品号 #17952_C

产品优势

产品组分包括

总览

实验数据

产品说明书及文档

应用领域

相关材料与文献

技术资料 (15)

常见问题

Can EasySep™ be used for either positive or negative selection?

How does the separation work?

Which columns do I use?

How can I analyze the purity of my enriched sample?

Can EasySep™ separations be automated?

Can EasySep™ be used to isolate rare cells?

Are the EasySep™ magnetic particles FACS-compatible?

Can the EasySep™ magnetic particles be removed after enrichment?

Can I alter the separation time in the magnet?

For positive selection, can I perform more than 3 separations to increase purity?

How does the binding of the EasySep™ magnetic particle affect the cells? is the function of positively selected cells altered by the bound particles?

文献 (38)

Abstract

Abstract

Abstract

Request Pricing

更多信息

欢迎您关注STEMCELL Technologies的微信公众平台